• COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557260PMC
http://dx.doi.org/10.1016/j.thromres.2020.10.004DOI Listing

Publication Analysis

Top Keywords

escalated-dose thromboprophylaxis
8
covid-19 associated
4
associated coagulopathy
4
coagulopathy thrombosis
4
thrombosis hemorrhage
4
hemorrhage mortality
4
mortality rates
4
rates escalated-dose
4
thromboprophylaxis strategy
4
strategy •
4

Similar Publications

Thrombotic complications from COVID-19 are now well known and contribute to significant morbidity and mortality. Different variants confer varying risks of thrombotic complications. Heparin has anti-inflammatory and antiviral effects.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effectiveness and safety of higher doses of anticoagulants in critically ill COVID-19 patients, as current guidelines on dosing are unclear.
  • It included six randomized controlled trials with about 2,130 patients, comparing escalated doses against standard doses of heparins.
  • Results indicated no significant difference in mortality rates, but higher doses reduced the risk of pulmonary embolism while increasing the risk of bleeding complications.
View Article and Find Full Text PDF

Background: Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable state and have an increased incidence of VTE. In response, CHEST issued rapid clinical guidance regarding prevention of VTE. Over the past 18 months the quality of the evidence has improved.

View Article and Find Full Text PDF

Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.

Thromb Haemost

January 2021

Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.

Background:  Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of escalated-dose pharmacologic thromboprophylaxis are not established.

Objectives:  To determine the pooled incidence of thrombosis/bleeding in hospitalized patients with COVID-19 for standard-dose, intermediate-dose, therapeutic anticoagulation, and no pharmacologic thromboprophylaxis.

View Article and Find Full Text PDF

• COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!